Introduction: Diabetes is described by unending hyperglycemia and causes long haul difficulties like retinopathy, neuropathy, and nephropathy. Most of the cancers in diabetes are associated with high blood glucose levels. An increase in glucose uptake can activate oncogenic pathways in cells, so this provides information that another pathway by which hyperglycemia increases cancer incidence risk. Objective: To correlate HbA1c with solid organ tumours in non-diabetic individuals. Methods: A cross-sectional study with convenient sampling. An HbA1c test was done for all the patients who were diagnosed with solid organ tumour at the time of admission and values were noted and HbA1c test was done for age and sex-matched otherwise healthy individuals and the values were noted. We compared the HbA1c values of each case and control. Any case or control with an HbA1c level above 6.5 was excluded from the study. Results: The mean HbA1c among the cases was 5.578 whereas among the controls was 5.303 and the p value is Significant (__ampersandsignlt;0.001).t-Value-3.597. The near-linear association of HbA1c levels with the risk of several cancers supports the conjecture that it might be possible to use HbA1c as an independent metabolic biomarker for cancer risk in diabetic or non-diabetic persons. Conclusion: It is a known fact that patients with diabetes are at increased risk of cancer but even in non-diabetics if the blood glucose levels are high they are also at increased risk of cancer. The risk is higher with Lung cancer, Colo-rectal cancers, Ovarian tumours and Gall bladder tumours. On the contrary patients with prostate cancer had lower HbA1c levels.